Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

@article{Facon2007MelphalanAP,
  title={Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial},
  author={Thierry Facon and J. Y. Mary and Cyrille Hulin and Lotfi Benboubker and Michel Attal and Brigitte P{\'e}gouri{\'e} and Marc Renaud and Jean Luc Harousseau and Gaelle Guillerm and Carine Chaleteix and Mamoun Dib and Laurent Voillat and Herv{\'e} Maisonneuve and Jacques Troncy and V{\'e}ronique Dorvaux and Mathieu Monconduit and Claude D Martin and Philippe Casassus and J{\'e}r{\^o}me Jaubert and Henry Jardel and Chantal Doyen and Brigitte Kolb and Bruno Anglaret and Bernard Grosbois and Ibrahim Yakoub-Agha and Claire Mathiot and Herv{\'e} Avet-Loiseau},
  journal={The Lancet},
  year={2007},
  volume={370},
  pages={1209-1218}
}
BACKGROUND In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. [...] Key MethodMETHODS Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg…Expand

Paper Mentions

Interventional Clinical Trial
Aim of this study is to evaluate Daratumumab effect on MRD-positive patients with Multiple Myeloma (MM) who achieved >VGPR after any therapy (ASCT, VMP, Rev-Dex). Daratumumab 16 mg/kg… Expand
ConditionsMyeloma Multiple
InterventionDrug
Interventional Clinical Trial
To evaluate: - the incidence of venous thromboembolic event (VTE) - the incidence of hemorrhagic complications, In a population of patients with myeloma who… Expand
ConditionsMyeloma, Venous Thromboembolism
InterventionDrug
Interventional Clinical Trial
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in very elderly patients. We… Expand
ConditionsNewly Diagnosed, Multiple Myeloma
InterventionDrug
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
TLDR
The results show an improved activity of MPT at a cost of increased toxicity, and it is believed that MPT can be considered one of the new standard of care for elderly or transplant-ineligible patients with MM. Expand
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
TLDR
Melphalan, prednisone, and lenalidomide, followed by lenalidmide maintenance therapy, showed promising results without severe neuropathy emerging, and MPR-R has no advantage over MPT-T concerning efficacy. Expand
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
  • C. Hulin, T. Facon, +17 authors P. Moreau
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphAlan andprednisone alone for prolonging survival in very elderly patients with newly diagnosed myeloma. Expand
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
TLDR
Although patients treated with MPT were relatively younger and had more frequent RI, better responses and less early mortality were observed in all age groups despite more frequent discontinuation. Expand
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
TLDR
In previously untreated, transplant ineligible, elderly myeloma patients, the addition of T to MP results in significantly improved RR and PFS with a trend towards improvement in OS compared with MP alone, but at a cost of significantly greater toxicity. Expand
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study
TLDR
ThaDD can be considered a therapeutic option in very elderly patients with MM since it induces a faster and deeper response than that obtained with MPT, having similar safety profile. Expand
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma – a retrospective population based study of 1162 patients
TLDR
Treatment with MPT gave a significantly better OS rate after both first and second line of therapy when compared with treatment with MP only, and the relative risk for death in the MPT group vs. the MP group was significantly lower. Expand
Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation
TLDR
Although incidences of some non-hematological toxicities tended to be higher in the MPT group, the low incidence of ≥ Grade 3 toxicities suggests that MPT therapy was well tolerated, and these results support the safety and efficacy of MPT Therapy in untreated Japanese multiple myeloma patients. Expand
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
TLDR
VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy, and appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse. Expand
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT) in newly diagnosed patients with myeloma showed significantly higher response rate and longerExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
TLDR
Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma and anticoagulant prophylaxis reduces frequency of thrombosis. Expand
Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial
TLDR
A first interim analysis was performed after the inclusion of 150 patients and a data safety monitoring board recommended a second analysis after the accrual of 200 patients, and the preliminary results are presented. Expand
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
TLDR
In elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features. Expand
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients.
TLDR
MEL100 was superior to MP in terms of complete remission rate, event-free survival, and overall survival in patients treated with 2 or 3 MEL100 courses followed by stem cell support. Expand
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.
TLDR
Overall, these results indicated that dexamethasone should not be routinely recommended as first-line treatment in elderly patients with MM, and the standard melphalan-prednisone remained the best treatment choice when efficacy and patient comfort were both considered. Expand
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
TLDR
This overview of randomized trials of CCT versus MP found no difference, either overall or within any subgroup, in mortality between CCT and MP, and these therapeutic options, as tested in the trials considered, are approximately equivalent. Expand
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
TLDR
When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival. Expand
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
  • A. Palumbo, P. Falco, +15 authors M. Petrucci
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Oral MPR therapy is a promising first-line treatment for elderly myeloma patients and aspirin appears to provide adequate antithrombosis prophylaxis. Expand
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
TLDR
Results support the use of intermittent courses of concurrent chemotherapy with large doses of melphalan and prednisone in patients with multiple myeloma. Expand
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
TLDR
Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70, and constitutes a more effective first-line regimen than standard treatment for elderly patients. Expand
...
1
2
3
...